Patrys shares rise as 10-year data shows PAT-SC1 improves survival

22 January 2014

Australian biotech companyPatrys (ASX: PAB) has published 10-year follow up data for its product PAT-SC1 showing that it is well-tolerated in gastric cancer patients and offers a significant survival benefit.

Patrys said it is currently seeking an out licensing partner for PAT-SC1. The company’s shares were trading 6.52% higher at $0.049 on Wednesday on the news.

This article in Oncology Reports is based on a study conducted between 1997 and 2001 that investigated the effect of PAT-SC1 in patients with gastric cancer who had also undergone gastric resection surgery. It has been previously shown that a single 20mg dose of PAT-SC1 administered before surgery induced cell killing in human primary gastric tumours, leading to tumour cell regression in over half of PAT-SC1-treated patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK